Lemaitre Vascular (LMAT) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Lemaitre Vascular (LMAT) do?
Lemaitre Vascular Inc (LMAT) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Manufactures and distributes specialized surgical implants and disposable instruments for peripheral vascular surgery. Operates a direct sales force supplying proprietary surgical tools directly to vascular surgeons worldwide. It is worth $1.71B on the market and sold $269.32M over the last year.
- Market cap
- $1.71B
- P/E ratio
- 27.7×
- Annual sales
- $269.32M
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Brief updated
- Nov 14, 2026
Brands and businesses behind LMAT
- Artegraft: Produces processed bovine carotid artery grafts sold to hospitals for vascular access and bypass procedures.
- XenoSure: Sells bovine pericardial surgical patches used for vascular reconstruction and cardiovascular repair to surgical centers.
- Pruitt: Supplies carotid shunts that maintain cerebral blood flow during endarterectomy operations in hospital operating rooms.
- Omniflow: Markets biosynthetic vascular prostheses used for peripheral bypass and arteriovenous access procedures.
LMAT’s flags, in plain English
Each flag is a number from Lemaitre Vascular’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.
Stupid Cash
Can pay this year's bills 14.2 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Wide Gross Margin
Gross margin of 70.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Fat Margins
Profit margin of 23.5%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.
Thinly Traded
Thinly traded, about 279 shares a day, so prices can swing. Few shares change hands each day, so the price can jump on small orders and buying or selling can cost more.
2 more green flags open with the free trial. Try it free for 7 days.
Questions about LMAT
How big is Lemaitre Vascular?
Lemaitre Vascular’s market cap is $1.71B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $269.32M: what customers paid the company over the last year, before any costs.
What is LMAT’s P/E ratio?
LMAT’s P/E ratio is 27.7×. Investors pay about 27.7 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with LMAT?
A strong U.S. dollar reduces the value of sales generated across international hospital markets. That is one risk on Lemaitre Vascular’s card. Its first risk flag is Thinly Traded, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Lemaitre Vascular’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. LMAT’s filings on SEC.gov. The Margin Monkey is research, not advice.
